Pulmonary Hypertension Innovator Pulnovo Medical Appoints Jessie Lian as CEO and Files for IPO

Recently, Pulnovo Medical announced the appointment of Ms. Jessie Lian as Chief Executive Officer and her addition to the Board of Directors, where she will assume full responsibility for the company’s business operations and management.

Ms. Lian Jia brings over 20 years of international leadership experience in commercialization, industrial strategy development, and global capital market operations. Prior to joining Pulnovo Medical, she held various positions at Johnson & Johnson, starting from frontline business roles and progressing to serve as Director of multiple business units, while also overseeing cross-functional operations and support departments. She later joined Cardinal Health as General Manager for China and Vice President of Strategic Marketing for the Asia-Pacific region. Following the spin-off of Cordis, she served as President for both China and the Asia-Pacific region. With a profound understanding of the healthcare landscape in China and the Asia-Pacific, Ms. Lian successfully led the domestic commercialization of the world’s first drug-eluting stent. She excels in driving corporate commercial transformation and business development (BD) marketization through innovative business perspectives and management approaches. Additionally, she has pioneered collaborative distribution models with domestic enterprises for both local and international markets, creating optimal opportunities for the company’s deployment in global capital markets and multidimensionally enhancing its strategic position. Ms. Lian holds a Bachelor’s degree in Biology from Peking University and an EMBA from CEIBS (China Europe International Business School).

Cynthia Chen, Chairman and President of Pulnovo MedicalStatement: The international medical market presents both opportunities and complexities, creating new possibilities for advancing patient-centric and effective medical solutions. With years of dedicated technological exploration, Pulnovo Medical is driven by a clinical innovation mission to address critical disease challenges, truly realizing the OTM (From Operation Table to Market) value proposition. Ms. Lian Jia brings extensive expertise in business, operations, and strategic development, complemented by outstanding leadership and a proven track record of success. We warmly welcome Ms. Lian Jia to Pulnovo Medical, where she will lead the expansion of our OTM innovation platform. As Pulnovo Medical enters a critical phase of growth and expansion, we are confident that Ms. Lian’s appointment will further drive the company’s strategic objectives, unlocking new possibilities for therapeutic advancement through superior quality, speed, efficiency, and cutting-edge innovative capabilities.

Ms. Lian JiaStatement: As the National 14th Five-Year Plan for the Pharmaceutical Industry gradually takes effect, trends such as industrial innovation and advanced manufacturing are beginning to lead the entire industry chain. The emergence of numerous disruptive innovations has spurred rapid transformation within the sector, while also presenting significant opportunities in the medical field. Leveraging a decade of technological accumulation and pioneering thinking in its niche, Pulnovo Medical is well-positioned to sustain its innovative momentum and respond more swiftly and effectively to the ever-changing industrial landscape. Pulnovo Medical has rapidly established itself as a track leader, demonstrating exceptional strength in shaping the global market structure through China’s original technologies. Yet, this is only the beginning. I look forward to supporting Pulnovo Medical in building upon its comprehensive industry chain capabilities to achieve new heights with the OTM innovation platform.

Pulnovo Medical, established in 2013, has always been driven by clinical value since its inception, committed to building a global OTM (Original Technology and Medicine) innovation platform with world-class original technologies. Through long-term value accumulation, Pulnovo Medical’s current product portfolio consists entirely of international firsts. The company has secured over 45 invention patents domestically and internationally, successfully entered the CFDA Green Channel for Innovative Medical Devices, and obtained CE quality system certification. In February 2021, Pulnovo Medical rapidly earned the US FDA Breakthrough Device Designation for its proprietary radiofrequency ablation catheter. Upholding a craftsmanship spirit dedicated to innovation and enhancing patients’ health resilience, Pulnovo Medical has swiftly emerged as a leader in interventional therapies for pulmonary hypertension. The company will continue to explore innovative treatments for heart failure, adhering to its fundamental mission and leveraging relentless R&D capabilities to usher patients into a new era.